0000946644-17-000002.txt : 20170213 0000946644-17-000002.hdr.sgml : 20170213 20170213144508 ACCESSION NUMBER: 0000946644-17-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170213 DATE AS OF CHANGE: 20170213 EFFECTIVENESS DATE: 20170213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEMISPHERX BIOPHARMA INC CENTRAL INDEX KEY: 0000946644 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 520845822 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-280579 FILM NUMBER: 17598354 BUSINESS ADDRESS: STREET 1: 1617 JFK BLVD, SUITE #500 STREET 2: ONE PENN CENTER CITY: PHILADELPHIA STATE: PA ZIP: 19103 BUSINESS PHONE: 215-988-0080 MAIL ADDRESS: STREET 1: 1617 JFK BLVD, SUITE #500 STREET 2: ONE PENN CENTER CITY: PHILADELPHIA STATE: PA ZIP: 19103 D 1 primary_doc.xml X0707 D LIVE 0000946644 HEMISPHERX BIOPHARMA INC 1617 JFK BLVD, SUITE #500 ONE PENN CENTER PHILADELPHIA PA PENNSYLVANIA 19103 215-988-0080 DELAWARE None None Corporation true Thomas K Equels 1617 JFK Blvd Philadelphia PA PENNSYLVANIA 19103 Executive Officer Director Adam Pascale 1617 JFK Blvd Philadelphia PA PENNSYLVANIA 19103 Executive Officer David Strayer 1617 JFK Blvd Philadelphia PA PENNSYLVANIA 19103 Executive Officer Wayne Springate 1617 JFK Blvd Philadelphia PA PENNSYLVANIA 19103 Executive Officer William Mitchell 1617 JFK Blvd Philadelphia PA PENNSYLVANIA 19103 Director Peter W Rodino 1617 JFK Blvd Philadelphia PA PENNSYLVANIA 19103 Executive Officer Stewart Appelrouth 1617 JFK Blvd Philadelphia PA PENNSYLVANIA 19103 Director Pharmaceuticals Decline to Disclose 06b false 2017-02-03 false true false 4545 H.C. Wainwright & Co., LLC 375 None None 430 Park Avenue New York NY NEW YORK 10022 FL FLORIDA NY NEW YORK TX TEXAS false 18182 18182 0 Warrants herein sold to investors when investors purchased registered shares. $01 of the total $0.55 per share purchase price of securities allocated to purchase of private warrants referred to herein. false 4 1273 true 0 represents same percentage of total commissions received for combination of public share and private warrant offering as set forth in item 13 above. 0 true false HEMISPHERX BIOPHARMA INC Thomas K. Equels Thomas K. Equels President 2017-02-13